Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Center for Neurologic Diseases, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Molecular Brain (Impact Factor: 4.35). 03/2009; 2:5. DOI: 10.1186/1756-6606-2-5
Source: PubMed

ABSTRACT Elevated SNCA gene expression and intracellular accumulation of the encoded alpha-synuclein (aSyn) protein are associated with the development of Parkinson disease (PD). To date, few enzymes have been examined for their ability to degrade aSyn. Here, we explore the effects of CTSD gene expression, which encodes the lysosomal protease cathepsin D (CathD), on aSyn processing.
Over-expression of human CTSD cDNA in dopaminergic MES23.5 cell cultures induced the marked proteolysis of exogenously expressed aSyn proteins in a dose-dependent manner. Unexpectedly, brain extractions, Western blotting and ELISA quantification revealed evidence for reduced levels of soluble endogenous aSyn in ctsd knock-out mice. However, these CathD-deficient mice also contained elevated levels of insoluble, oligomeric aSyn species, as detected by formic acid extraction. In accordance, immunohistochemical studies of ctsd-mutant brain from mice, sheep and humans revealed selective synucleinopathy-like changes that varied slightly among the three species. These changes included intracellular aSyn accumulation and formation of ubiquitin-positive inclusions. Furthermore, using an established Drosophila model of human synucleinopathy, we observed markedly enhanced retinal toxicity in ctsd-null flies.
We conclude from these complementary investigations that: one, CathD can effectively degrade excess aSyn in dopaminergic cells; two, ctsd gene mutations result in a lysosomal storage disorder that includes microscopic and biochemical evidence of aSyn misprocessing; and three, CathD deficiency facilitates aSyn toxicity. We therefore postulate that CathD promotes 'synucleinase' activity, and that enhancing its function may lower aSyn concentrations in vivo.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We developed an assay system for aggregate formation using α-Syn-ECFP-expressing cells.•The α-Syn fibril-induced intracellular aggregate formation required lysosomal function.•Cathepsin B enhanced the seeding activity of α-Syn fibrils.•Exogenous α-Syn fibrils nucleated and developed early aggregates in the lysosome.
    Neurobiology of Disease 01/2015; 73. · 5.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Kallikrein-6 and calpain-1 are amongst a small group of proteases that degrade ¿-synuclein. We have explored the possibility that reduction in the level or activity of these enzymes contributes to the accumulation of ¿-synuclein in Lewy body diseases. We measured calpain-1 activity by fluorogenic activity assay, kallikrein-6 level by sandwich ELISA, and levels of ¿-synuclein and ¿-synuclein phosphorylated at serine 129 (¿-synuclein-P129), in post-mortem brain tissue in pure dementia with Lewy bodies (DLB, n = 12), Alzheimer¿s disease (AD, n = 20) and age-matched controls (n = 19). Calpain-1 activity was significantly reduced in DLB within the cingulate and parahippocampal cortex, regions with highest ¿-synuclein and ¿-synuclein-P129 load, and correlated inversely with the levels of ¿-synuclein and ¿-synuclein-P129. Calpain-1 was unaltered in the thalamus and frontal cortex, regions with less ¿-synuclein pathology. Kallikrein-6 level was reduced in the cingulate cortex in the DLB cohort, and correlated inversely with ¿-synuclein and ¿-synuclein-P129. Kallikrein-6 was also reduced in DLB in the thalamus but not in relation to ¿-synuclein or ¿-synuclein-P129 load and was unaltered in the frontal and parahippocampal cortex. In SH-SY5Y cells overexpressing wild-type ¿-synuclein there was partial co-localisation of kallikrein-6 and calpain-1 with ¿-synuclein, and siRNA-mediated knock-down of kallikrein-6 and calpain-1 increased the amount of ¿-synuclein in cell lysates. Our results indicate that reductions in kallikrein-6 and calpain-1 may contribute to the accumulation of ¿-synuclein in DLB.
    Acta neuropathologica communications. 12/2014; 2(1):164.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Converging lines of evidence suggest that cell-to-cell transmission and the self-propagation of pathogenic amyloidogenic proteins play a central role in the initiation and the progression of several neurodegenerative disorders. This "prion-like" hypothesis has been recently reported for α-synuclein, a presynaptic protein implicated in the pathogenesis of Parkinson's disease (PD) and related disorders. This review summarizes recent findings on α-synuclein prion-like propagation, focusing on its transmission, seeding and degradation and discusses some key questions that remain to be explored. Understanding how α-synuclein exits cells and propagates from one brain region to another will lead to the development of new therapeutic strategies for the treatment of PD, aiming at slowing or stopping the disease progression.
    Experimental neurobiology. 12/2014; 23(4):324-36.

Full-text (2 Sources)

Available from
May 21, 2014